Q3 2022 Results slide image

Q3 2022 Results

Company overview Financial review Financial performance Cardiovascular Immunology 2022 priorities Innovation: Pipeline overview Cardiovascular Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 44 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation